{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T17:10:57Z","timestamp":1780420257924,"version":"3.54.1"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,6,2]]},"DOI":"10.7759\/cureus.110130","type":"journal-article","created":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T16:36:07Z","timestamp":1780418167000},"source":"Crossref","is-referenced-by-count":0,"title":["Evaluation of p53 Expression in Megakaryocytes Enhances Detection of TP53 Mutations and Residual Disease in Myeloid Neoplasms"],"prefix":"10.7759","author":[{"given":"Linlin","family":"Gao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonah S","family":"Rong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Da","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janet","family":"Woodroof","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Cui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1038\/320084a0","article-title":"Localization of gene for human p53 tumour antigen to band 17p13","volume":"320","author":"Isobe M","year":"1986","unstructured":"Isobe M, Emanuel BS, Givol D, Oren M, Croce CM. Localization of gene for human p53 tumour antigen to band 17p13. Nature. 1986, 320:84-5. 10.1038\/320084a0","journal-title":"Nature"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/s0092-8674(00)81871-1","article-title":"p53, the cellular gatekeeper for growth and division","volume":"88","author":"Levine AJ","year":"1997","unstructured":"Levine AJ. p53, the cellular gatekeeper for growth and division. Cell. 1997, 88:323-31. 10.1016\/s0092-8674(00)81871-1","journal-title":"Cell"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1038\/nm1087","article-title":"Cancer genes and the pathways they control","volume":"10","author":"Vogelstein B","year":"2004","unstructured":"Vogelstein B, Kinzler KW. Cancer genes and the pathways they control. Nat Med. 2004, 10:789-99. 10.1038\/nm1087","journal-title":"Nat Med"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1038\/nrc2723","article-title":"The first 30 years of p53: growing ever more complex","volume":"9","author":"Levine AJ","year":"2009","unstructured":"Levine AJ, Oren M. The first 30 years of p53: growing ever more complex. Nat Rev Cancer. 2009, 9:749-58. 10.1038\/nrc2723","journal-title":"Nat Rev Cancer"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.12203","article-title":"TP53 mutations in myelodysplastic syndrome are strongly correlated with aberrations of chromosome 5, and correlate with adverse prognosis","volume":"160","author":"Kulasekararaj AG","year":"2013","unstructured":"Kulasekararaj AG, Smith AE, Mian SA, et al.. TP53 mutations in myelodysplastic syndrome are strongly correlated with aberrations of chromosome 5, and correlate with adverse prognosis. Br J Haematol. 2013, 160:660-72. 10.1111\/bjh.12203","journal-title":"Br J Haematol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-015-0139-z","article-title":"TP53 mutation characteristics in therapy-related myelodysplastic syndromes and acute myeloid leukemia is similar to de novo diseases","volume":"8","author":"Ok CY","year":"2015","unstructured":"Ok CY, Patel KP, Garcia-Manero G, et al.. TP53 mutation characteristics in therapy-related myelodysplastic syndromes and acute myeloid leukemia is similar to de novo diseases. J Hematol Oncol. 2015, 8:45. 10.1186\/s13045-015-0139-z","journal-title":"J Hematol Oncol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2015.59","article-title":"TP53 mutations in de novo acute myeloid leukemia patients: longitudinal follow-ups show the mutation is stable during disease evolution","volume":"5","author":"Hou HA","year":"2015","unstructured":"Hou HA, Chou WC, Kuo YY, et al.. TP53 mutations in de novo acute myeloid leukemia patients: longitudinal follow-ups show the mutation is stable during disease evolution. Blood Cancer J. 2015, 5:e331. 10.1038\/bcj.2015.59","journal-title":"Blood Cancer J"},{"key":"ref8","article-title":"Myelodysplastic neoplasm with biallelic TP53 inactivation","author":"Germing U","year":"2022","unstructured":"Germing U, Ades L, Fontenay M, et al.. Myelodysplastic neoplasm with biallelic TP53 inactivation. WHO Classification of Tumours, Haematolymphoid Tumours. Akkari Y, Alaggio R, Campbell PJ (ed): International Agency for Research on Cancer, Lyon; 2022. 80-84."},{"key":"ref9","article-title":"Myelodysplastic Syndrome With Mutated TP53","author":"Yabe M","year":"2025","unstructured":"Yabe M, Hasserjian RP, Sallman DA, Weinberg OK. Myelodysplastic Syndrome With Mutated TP53. The International Consensus Classification of Myeloid and Lymphoid Neoplasms. Arber D, Borowitz MJ, Cook J, et al. (ed): Lippincott Williams & Wilkins, 2025. 140-144."},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1013343","article-title":"Clinical effect of point mutations in myelodysplastic syndromes","volume":"364","author":"Bejar R","year":"2011","unstructured":"Bejar R, Stevenson K, Abdel-Wahab O, et al.. Clinical effect of point mutations in myelodysplastic syndromes. N Engl J Med. 2011, 364:2496-506. 10.1056\/NEJMoa1013343","journal-title":"N Engl J Med"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2014.55","article-title":"Comprehensive analysis of genetic alterations and their prognostic impacts in adult acute myeloid leukemia patients","volume":"28","author":"Kihara R","year":"2014","unstructured":"Kihara R, Nagata Y, Kiyoi H, et al.. Comprehensive analysis of genetic alterations and their prognostic impacts in adult acute myeloid leukemia patients. Leukemia. 2014, 28:1586-95. 10.1038\/leu.2014.55","journal-title":"Leukemia"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1038\/modpathol.2014.153","article-title":"High p53 protein expression in therapy-related myeloid neoplasms is associated with adverse karyotype and poor outcome","volume":"28","author":"Cleven AH","year":"2015","unstructured":"Cleven AH, Nardi V, Ok CY, et al.. High p53 protein expression in therapy-related myeloid neoplasms is associated with adverse karyotype and poor outcome. Mod Pathol. 2015, 28:552-63. 10.1038\/modpathol.2014.153","journal-title":"Mod Pathol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2016.263","article-title":"The impact of TP53 mutations and TP53 deletions on survival varies between AML, ALL, MDS and CLL: an analysis of 3307 cases","volume":"31","author":"Stengel A","year":"2017","unstructured":"Stengel A, Kern W, Haferlach T, Meggendorfer M, Fasan A, Haferlach C. The impact of TP53 mutations and TP53 deletions on survival varies between AML, ALL, MDS and CLL: an analysis of 3307 cases. Leukemia. 2017, 31:705-11. 10.1038\/leu.2016.263","journal-title":"Leukemia"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2021014472","article-title":"Molecular characterization of mutant TP53 acute myeloid leukemia and high-risk myelodysplastic syndrome","volume":"139","author":"Grob T","year":"2022","unstructured":"Grob T, Al Hinai AS, Sanders MA, et al.. Molecular characterization of mutant TP53 acute myeloid leukemia and high-risk myelodysplastic syndrome. Blood. 2022, 139:2347-54. 10.1182\/blood.2021014472","journal-title":"Blood"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2013.098103","article-title":"p53 protein expression independently predicts outcome in patients with lower-risk myelodysplastic syndromes with del(5q)","volume":"99","author":"Saft L","year":"2014","unstructured":"Saft L, Karimi M, Ghaderi M, et al.. p53 protein expression independently predicts outcome in patients with lower-risk myelodysplastic syndromes with del(5q). Haematologica. 2014, 99:1041-9. 10.3324\/haematol.2013.098103","journal-title":"Haematologica"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2016.143214","article-title":"Immunohistochemical pattern of p53 is a measure of TP53 mutation burden and adverse clinical outcome in myelodysplastic syndromes and secondary acute myeloid leukemia","volume":"101","author":"McGraw KL","year":"2016","unstructured":"McGraw KL, Nguyen J, Komrokji RS, et al.. Immunohistochemical pattern of p53 is a measure of TP53 mutation burden and adverse clinical outcome in myelodysplastic syndromes and secondary acute myeloid leukemia. Haematologica. 2016, 101:e320-3. 10.3324\/haematol.2016.143214","journal-title":"Haematologica"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1111\/ijlh.13316","article-title":"High-level MYC expression associates with poor survival in patients with acute myeloid leukemia and collaborates with overexpressed p53 in leukemic transformation in patients with myelodysplastic syndrome","volume":"43","author":"Gao L","year":"2021","unstructured":"Gao L, Saeed A, Golem S, et al.. High-level MYC expression associates with poor survival in patients with acute myeloid leukemia and collaborates with overexpressed p53 in leukemic transformation in patients with myelodysplastic syndrome. Int J Lab Hematol. 2021, 43:99-109. 10.1111\/ijlh.13316","journal-title":"Int J Lab Hematol"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.4084\/MJHID.2019.015","article-title":"Prognostic impact of immunohistochemical p53 expression in bone marrow biopsy in higher risk MDS: a pilot study","volume":"11","author":"Molteni A","year":"2019","unstructured":"Molteni A, Ravano E, Riva M, et al.. Prognostic impact of immunohistochemical p53 expression in bone marrow biopsy in higher risk MDS: a pilot study. Mediterr J Hematol Infect Dis. 2019, 11:e2019015. 10.4084\/MJHID.2019.015","journal-title":"Mediterr J Hematol Infect Dis"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.25255","article-title":"P53 protein overexpression in de novo acute myeloid leukemia patients with normal diploid karyotype correlates with FLT3 internal tandem duplication and worse relapse-free survival","volume":"93","author":"Assi R","year":"2018","unstructured":"Assi R, Gur HD, Loghavi S, et al.. P53 protein overexpression in de novo acute myeloid leukemia patients with normal diploid karyotype correlates with FLT3 internal tandem duplication and worse relapse-free survival. Am J Hematol. 2018, 93:1376-83. 10.1002\/ajh.25255","journal-title":"Am J Hematol"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2014.104760","article-title":"Response to azacitidine is independent of p53 expression in higher-risk myelodysplastic syndromes and secondary acute myeloid leukemia","volume":"99","author":"M\u00fcller-Thomas C","year":"2014","unstructured":"M\u00fcller-Thomas C, Rudelius M, Rondak IC, et al.. Response to azacitidine is independent of p53 expression in higher-risk myelodysplastic syndromes and secondary acute myeloid leukemia. Haematologica. 2014, 99:e179-81. 10.3324\/haematol.2014.104760","journal-title":"Haematologica"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1093\/ajcp\/aqae034","article-title":"p53 immunohistochemistry as an ancillary tool for rapid assessment of residual disease in TP53-mutated acute myeloid leukemia and myelodysplastic syndromes","volume":"162","author":"Brar N","year":"2024","unstructured":"Brar N, Lawrence L, Fung E, et al.. p53 immunohistochemistry as an ancillary tool for rapid assessment of residual disease in TP53-mutated acute myeloid leukemia and myelodysplastic syndromes. Am J Clin Pathol. 2024, 162:269-81. 10.1093\/ajcp\/aqae034","journal-title":"Am J Clin Pathol"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1159\/isbn.978-3-318-07331-7","article-title":"ISCN 2024: An International System for Human Cytogenomic Nomenclature","year":"2024","unstructured":"ISCN 2024. An International System for Human Cytogenomic Nomenclature. Hastings RJ, Moore S, Chia N (ed): Karger, Basel; 2024. 10.1159\/isbn.978-3-318-07331-7"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1111\/ijlh.13711","article-title":"Comparison of flow cytometry and next-generation sequencing in minimal residual disease monitoring of acute myeloid leukemia: one institute's practical clinical experience","volume":"44","author":"F McGowan P","year":"2022","unstructured":"F McGowan P, D Hyter S, Cui W, Plummer RM, Godwin AK, Zhang D. Comparison of flow cytometry and next-generation sequencing in minimal residual disease monitoring of acute myeloid leukemia: one institute's practical clinical experience. Int J Lab Hematol. 2022, 44:118-26. 10.1111\/ijlh.13711","journal-title":"Int J Lab Hematol"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1038\/gim.2015.30","article-title":"Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology","volume":"17","author":"Richards S","year":"2015","unstructured":"Richards S, Aziz N, Bale S, et al.. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med. 2015, 17:405-24. 10.1038\/gim.2015.30","journal-title":"Genet Med"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/487892-evaluation-of-p53-expression-in-megakaryocytes-enhances-detection-of-tp53-mutations-and-residual-disease-in-myeloid-neoplasms","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T16:36:08Z","timestamp":1780418168000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/487892-evaluation-of-p53-expression-in-megakaryocytes-enhances-detection-of-tp53-mutations-and-residual-disease-in-myeloid-neoplasms"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,2]]},"references-count":24,"URL":"https:\/\/doi.org\/10.7759\/cureus.110130","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6,2]]}}}